Immedica Publishes Annual & Sustainability Report for 2024
Stockholm, Sweden - May 13, 2025 - Immedica today announces the publication of its Annual & Sustainability Report for 2024, highlighting a year of strategic transformation and continued commitment to improving the lives of people with rare diseases.
The report outlines several key developments, including a revised ownership structure backed by investment firms KKR and Impilo AB, and the establishment of a U.S. commercial hub-signifying Immedica's expansion into the world's largest pharmaceutical market. The company also strengthened its portfolio through a strategic acquisition and achieved its first proprietary product launch in multiple international regions.
Immedica's culture played a central role in enabling this progress. With strong cross-functional collaboration and a clear shared purpose, the organization continued to deliver results with quality and speed. In 2024, Immedica was proud to be recognized as a Great Place to Work® for the second year in a row. The company was also ranked top 2 in Sweden's best workplaces in 2025 based on these Great Place To Work results.
Reflecting on the past year, Anders Edvell, CEO of Immedica, commented:
"2024 was a transformative year for Immedica, marked by milestones that only a few years back were unimaginable to us. We took significant steps toward our goal of becoming a global leader in rare diseases. These efforts are not only reshaping our business-they are making a real difference in the lives of patients worldwide."
As the company looks ahead, Immedica remains focused on expanding its international footprint, strengthening its portfolio, and continuing to build an agile, value-driven organization capable of making a meaningful difference for people living with rare diseases.
The full Annual & Sustainability Report 2024 is available on Immedica's website: www.immedica.com
About Immedica
Immedica is a pharmaceutical company, headquartered in Stockholm, Sweden, focused on the commercialization of medicines for rare diseases and specialty care products. Immedica's capabilities cover marketing and sales, compliance, pharmacovigilance, quality assurance, regulatory, medical affairs and market access, as well as a global distribution network serving patients in more than 50 countries. Immedica is fully dedicated to helping those living with diseases which have a large unmet medical need. Immedica's therapeutic areas are within RARE metabolic, RARE hematology & oncology, RARE neurology and specialty care. Immedica was founded in 2018 and employs today around 140 people across Europe, the Middle East and the United States. Immedica is backed by the investment firms KKR and Impilo.
For more information visit www.immedica.com.
Immedica contact:
Linda Holmström
VP, Head of HR & Communication
[email protected]
+ 46 708 73 40 95
